Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - Henan Huarong Biotechnology
Alternative Names: Anti-CD19 CAR-T Cell Therapy - Henan huarong biotechnologyLatest Information Update: 23 Mar 2021
Price :
$50
*
At a glance
- Originator Henan Huarong Biotechnology
- Developer Henan Huarong Biotechnology; Luoyang Central Hospital Affiliated to Zhengzhou University; The First Affiliated Hospital of Xinxiang Medical University
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 23 Mar 2021 Anti-CD19 chimeric antigen receptor T cell therapy is still in phase II trials for Precursor cell lymphoblastic leukaemia-lymphoma in China (ChiCTR1800018210) (ChiCTR1800018211)
- 01 Sep 2018 Phase-II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (Recurrent, Refractory metastatic disease, Second-line therapy or greater) in China (Parenteral) (ChiCTR1800018210)
- 01 Sep 2018 Phase-II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (Recurrent, Refractory metastatic disease, Second-line therapy or greater, In children, In adolescents, In adults, In the elderly) in China (Parenteral) (ChiCTR1800018211)